Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ospedale San Raffaele S R L manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 3 pending office actions. These actions are distributed among 3 distinct examiners and 3 distinct art units. MARCHESCHI, MICHAEL A is the busiest examiner with 1 busiest examiner pending action. This distribution means that every pending office action is being handled by a different examiner in a different art unit.
Practitioners must manage 3 separate prosecution tracks, each with its own examiner and art unit standards. The presence of 3 distinct examiners across 3 art units indicates a range of technical subject matter within the Biotechnology & Pharmaceuticals portfolio. Because the workload is split, with each examiner responsible for only 1 busiest examiner pending action, there is no central point of influence in the current prosecution. This fragmentation requires an individualized approach for each filing. Success in 1 art unit may not translate to others, as the 3 distinct examiners will likely apply different interpretations of patentability within their respective 3 art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARCHESCHI, MICHAEL A | 1 | 20.0% | +17.9% |
| BARSKY, JARED | 1 | 50.2% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042376 | DEVICE FOR BIOLOGICAL CULTURES | MARCHESCHI, MICHAEL A | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17910971 | TREATMENT OF STEM CELL DEFICIENCY | BARSKY, JARED | 20d |
| 18042376 | DEVICE FOR BIOLOGICAL CULTURES | MARCHESCHI, MICHAEL A | 21d |
| Art Unit | Apps |
|---|---|
| 1796 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18042376 | DEVICE FOR BIOLOGICAL CULTURES | MARCHESCHI, MICHAEL A | 1796 | §102§103§112 | Final Rejection | 21d | Pending | Feb 21, 2023 |
| 17910971 | TREATMENT OF STEM CELL DEFICIENCY | BARSKY, JARED | 1628 | §102§103DP | Final Rejection | 20d | Pending | Sep 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial